Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of West Pharmaceutical Services, Inc. (WST)

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of West Pharmaceutical Services, Inc. (NYSE: WST) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have held shares continuously since prior to the date listed below may have standing to seek corporate governance reforms focused on executive oversight, the return of funds to the Company, and a court-approved incentive award, at no cost to them.

If you have held West Pharmaceutical shares continuously since prior to February 16, 2023, you may have standing to seek corporate governance reforms focused on executive oversight at West Pharmaceutical.

Complaint Allegations

A previously filed securities class action complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:

1. Despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West Pharmaceutical was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio;
2. West Pharmaceutical’s SmartDose device, which was positioned as a high-margin growth product, was highly dilutive to profit margins due to operational inefficiencies; and
3. These margin pressures created the risk of costly restructuring activities, including the Company’s exit from continuous glucose monitoring (“CGM”) contracts with long-standing customers.